NVAX240719C23000
- 0.17
- +0.10+142.86%
Novavax Newsroom
Does Novavax's (NASDAQ:NVAX) Pullback Could Signal a Buying Opportunity
B of A Securities Maintains Neutral on Novavax, Raises Price Target to $18
Novavax Analyst Ratings
Novavax Analyst Ratings
Novavax (NVAX) Was Upgraded to a Hold Rating at J.P. Morgan
Novavax Analyst Ratings
Novavax Analyst Ratings
Novavax Analyst Ratings
B of A Securities Upgrades Novavax to Neutral, Raises Price Target to $12
Buy Rating for Novavax Amid Strategic Sanofi Partnership and Solid Financial Prospects
Novavax Analyst Ratings
Maintaining Hold on Novavax: Assessing Current Performance and Future Market Penetration Strategies
Optimizing for Growth: Novavax's Settlement, Cost Reductions, and CIC Vaccine Propel Buy Rating
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Align Tech (ALGN) and Novavax (NVAX)
B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX) and Verrica Pharmaceuticals (VRCA)
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Rani Therapeutics Holdings (RANI) and Novavax (NVAX)
Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA), Novavax (NVAX) and Sanofi (OtherSNYNF)
Novavax's Matrix-M COVID-19 Vaccine Receives Buy Rating Following FDA's Emergency Use Authorization Amendment and Anticipated Demand Surge
B.Riley Financial Reaffirms Their Buy Rating on Novavax (NVAX)